BackNeoImmuneTech Overview

NeoImmuneTech EBIT

Track NeoImmuneTech's EBIT ($-24B) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

-$3.53B
↑ 21.61% YoY

As of Sep 30, 2026

Annual EBIT (TTM)

-$24.33B
↑ 10.46% YoY

Trailing 12 months ending Sep 30, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

NeoImmuneTech (950220.KQ) FAQ

The latest EBIT for 950220.KQ is $-24B as of September 2026. That compares with $-27B in the prior-year period — up 10.5% year over year. That is below the Healthcare sector average of $1.1T. Investors often review this figure alongside NeoImmuneTech's historical trend and sector peers before judging valuation or financial health.

Over the past year, 950220.KQ's EBIT moved from $-27B to $-24B — a 10.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in NeoImmuneTech's operating scale or balance-sheet position.

Against Healthcare companies, 950220.KQ currently prints $-24B for EBIT, while the sector average sits near $1.1T. That is roughly 102.2% below the sector mean. Large gaps often invite a closer look at NeoImmuneTech's growth, margins, and balance sheet.

A EBIT figure of $-24B for 950220.KQ is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $1.1T. Explore the charts below for those layers of context.

After noting 950220.KQ's EBIT ($-24B), review year-over-year change from $-27B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

Questions & Answers